Newsfeeds - Spark Newswire

4 minute read

Options

10 Health Care Stocks Showing Unusual Options Activity In Today’s Session

Today, 7:45 PM

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.

CVS

2 minute read

Movers

Unusual Options Activity Insight: Immutep

By Benzinga Insights

Today, 7:45 PM

Shares of Immutep (NASDAQ:IMMP) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved up to $3.77.

IMMP

1 minute read

Immutep Announced Wednesday 1st Patient Dosed in INSIGHT-003 investigator-initiated Trial

By Charles Gross

Today, 7:45 PM

Immutep Limited (NASDAQ: IMMP) is pleased to announce that the first patient has been enrolled and safely dosed in INSIGHT-003.

IMMP

1 minute read

Ladenburg Thalmann Initiates Coverage On Immutep with Buy Rating, Announces Price Target of $8.3

By Benzinga Newsdesk

Today, 7:45 PM

Ladenburg Thalmann initiates coverage on Immutep (NASDAQ:IMMP) with a Buy rating and announces Price Target of $8.3.

IMMP

1 minute read

Immutep Limited Announced FDA and IRB Approval in the US for Phase IIb TACTI-003 Trial in HNSCC

By Charles Gross

Today, 7:45 PM

Immutep Limited (NASDAQ: IMMP) announces it has completed all the necessary competent authority steps with the US Food and Drug Administration (FDA) and has received IRB approval to commence its phase IIb TACTI-003 trial in the United States.

IMMP

1 minute read

12 Health Care Stocks Moving In Tuesday’s Pre-Market Session

By Benzinga Insights

Today, 7:45 PM

ADIL

1 minute read

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

Today, 7:45 PM

AHCO

2 minute read

FDA
News

Immutep Reports Will Evaluate Efti In Triple Combo Therapy Phase 1 Study With Chemotherapy, Anti-PD-1 Therapy

By Benzinga Newsdesk

Today, 7:45 PM

New Phase I clinical trial, called INSIGHT-003, in patients with various solid tumours Expands the evaluation of efti into a triple combination therapy of efti, chemotherapy and anti-PD-1 therapy First patient in

IMMP

1 minute read

Immutep To Initiate Efti Triple Combination Therapy Trial In Solid Tumors, Launches $60M Placement

By Vandana Singh

Today, 7:45 PM

Immutep (NASDAQ:IMMP) will begin a Phase 1 trial to evaluate its lead product candidate, eftilagimod alpha (efti or IMP321), in conjunction…

IMMP

2 minute read

Immutep Announced it Will Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

By Charles Gross

Today, 7:45 PM

Immutep Limited (NASDAQ: IMMP) announces it has signed an agreement to commence a new Phase I trial, called INSIGHT-003, to evaluate the combination of lead product candidate eftilagimod alpha ("efti" or "IMP321") in conjunction with an existing approved standard of care therapy consisting of a chemotherapy agent and ananti-P

IMMP